Phio Pharmaceuticals
PHIO
9 hedge funds and large institutions have $511K invested in Phio Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 2 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
0% less ownership
Funds ownership: 0% → 0% (-0%)
14% less capital invested
Capital invested by funds: $591K → $511K (-$80K)
18% less funds holding
Funds holding: 11 → 9 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG Americas Securities
New York
|
+$165K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$21K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$7.87K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$7.87K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$107K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$89.2K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
SG Americas Securities
New York
| $229K | +$165K | +63 | +162% |
|
|
CH
2
CVI Holdings
Wilmington,
Delaware
| $154K | -$89.2K | -34 | -33% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $45K | +$7.87K | +3 | +18% |
|
|
4
Citadel Advisors
Miami,
Florida
| $33K | +$21K | +8 | +133% |
|
|
TSS
5
Two Sigma Securities
New York
| $18K | +$7.87K | +3 | +60% |
|
|
6
UBS Group
Zurich,
Switzerland
| $14K | +$5.25K | +2 | +50% |
|
7
Vanguard Group
Malvern,
Pennsylvania
| $10K | – | – | – |
|
8
Renaissance Technologies
New York
| $6K | +$2.62K | +1 | +50% |
|
9
Morgan Stanley
New York
| $2K | – | – | – |
|
|
KFS
10
Kelly Financial Services
Braintree,
Massachusetts
| $2 | – | – | – |
|
|
VF
11
Virtu Financial
New York
| – | -$107K | -40 | Closed |
|
|
12
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$3K | -1 | Closed |
|
PHIO Hedge Fund Activity: Q2 2019 in Review
9 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q2 2019, worth a combined $511K — down 14% from $591K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of PHIO and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 6 added.
The largest buyer was SG Americas Securities, adding an estimated $165K. The largest seller was Virtu Financial, exiting entirely with an estimated $107K sold.
- 9 institutional investors held Phio Pharmaceuticals (PHIO) as of Q2 2019, down from 11 in Q1 2019.
- Funds reported $511K of Phio Pharmaceuticals stock for Q2 2019, down 14% quarter-over-quarter.
- 0 funds opened new Phio Pharmaceuticals positions in Q2 2019 and 2 closed out, a net change of -2 holders.
- The largest Phio Pharmaceuticals buyer in Q2 2019 was SG Americas Securities, an estimated $165K added.
- The largest Phio Pharmaceuticals seller in Q2 2019 was Virtu Financial, an estimated $107K sold.
Based on aggregated 13F filings for Q2 2019.